06 Jun
  • By Sha
  • Cause in

Nonprofit CureDuchenne is Encouraged to See Gene Editing for Duchenne Advance Through Vertex’s Acquisition of Exonics Therapeutics

Deal will accelerate drug development for Duchenne muscular dystrophy, a rare disease that affects 300,000 boys and young men worldwide June 06, 2019 07:11 PM Eastern Daylight Time NEWPORT BEACH, Calif.–(BUSINESS WIRE)–CureDuchenne, a nonprofit global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy […]

READ MORE
01 May
  • By Jessica Yanez-Perez
  • Cause in

Champions to CureDuchenne Magical Night Under the Stars Raises Over $400,000 for Research to Find Cure for Duchenne Muscular Dystrophy

NEWPORT BEACH, CA (April 24, 2019) —  Austin’s finest recently came together for Champions to CureDuchenne, an annual charity event that benefits CureDuchenne, a national nonprofit that funds research to find a cure for Duchenne muscular dystrophy, the most devastating and lethal muscular disease in children. One in every 5,000 boys will be diagnosed with […]

READ MORE
28 Feb
  • By Jessica Yanez-Perez
  • Cause in

Inaugural “Love Cures” Event Raises Funds to Help Find a Cure for Duchenne Muscular Dystrophy

Funds raised will be donated to the national nonprofit, CureDuchenne NEWPORT BEACH, Calif., Feb. 28, 2019 – The inaugural “Love Cures” event recently held in San Diego at the Del Sur Ranch House raised $45,000 to help find a cure for Duchenne muscular dystrophy, a devastating, progressive muscle-wasting disease affecting 15,000 boys and young men […]

READ MORE
26 Feb
  • By Jessica Yanez-Perez
  • Cause in

CureDuchenne Cares Announces Annual FUTURES Conference and Line-up of 30 Educational Events for Duchenne Community in 2019

NEWPORT BEACH, Calif., Feb 26, 2019 – CureDuchenne, the nonprofit global leader in Duchenne research, patient care and innovation, announced today that its CureDuchenne Cares program will offer the Duchenne community 30 free educational events across the United States in 2019.  This includes the second annual “FUTURES” conference, which is set for October 11 -13, […]

READ MORE
05 Nov
  • By Matter Now
  • Cause in

CureDuchenne and Avidity Biosciences Host Webinar on Pre-clinical Development of Novel Exon Skipping Therapies for Duchenne Muscular Dystrophy

Newport Beach, Calif. (November 5, 2018) – CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (DMD), announced today it will host a webinar with Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon […]

READ MORE
17 Oct
  • By Matter Now
  • Cause in

Avidity Biosciences Receives Investment from CureDuchenne

Investment advances pre-clinical development of novel exon skipping therapies for treatment of patients with Duchenne muscular dystrophy October 17, 2018 08:00 AM Eastern Daylight Time LA JOLLA, Calif.–(BUSINESS WIRE)–Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates, announced today that CureDuchenne has made an equity investment […]

READ MORE
17 Oct
  • By Matter Now
  • Cause in

CureDuchenne Invests in ZappRx Platform to Develop Specialty Prescribing Application for Patients Suffering from Duchenne Muscular Dystrophy

Nonprofit invests in leading specialty prescription and prior authorization solution provider to get Duchenne patients breakthrough medications, faster October 17, 2018 08:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–ZappRx, Inc., a digital health company that streamlines specialty medication prescribing, announced today that CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the […]

READ MORE
09 Oct
  • By Matter Now
  • Cause in

CureDuchenne Hosts “Futures” Conference in Boston, November 3-4

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Caregivers of Duchenne muscular dystrophy and patients suffering from the rare disease on the east coast will have an opportunity to learn about the best practices of care for Duchenne at a conference titled “Futures” hosted by nonprofit CureDuchenne. CureDuchenne Futures will be held on November 3rd and 4th, 2018 at the […]

READ MORE
04 Oct
  • By Matter Now
  • Cause in

CureDuchenne Partners with Baebies to Accelerate Newborn Screening for Duchenne Muscular Dystrophy

Strategic investment and collaboration provide new parents with easy-to-access innovative screening option to positively impact the earliest stages of the Duchenne care continuum NEWPORT BEACH, Calif.–(BUSINESS WIRE) – CureDuchenne, the nation’s leading nonprofit funding scientific research and innovation for Duchenne muscular dystrophy, announced today it has entered into a three-year partnership with Baebies. A growth-stage […]

READ MORE
07 Sep
  • By CureDuchenne User
  • Cause in

CureDuchenne Ventures Commits $500,000 to 4D Molecular Therapeutics to Advance Next-Generation AAV Delivery of Gene Therapy

NEWPORT BEACH, Calif. – (BUSINESS WIRE) – CureDuchenne, a national venture philanthropy nonprofit focused on finding a cure for Duchenne muscular dystrophy (DMD), announced today a $500,000 investment into 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, in an effort to advance […]

READ MORE